• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Intelligent Bio Solutions Inc.

    2/4/25 9:14:36 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care
    Get the next $INBS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    INTELLIGENT BIO SOLUTIONS INC.

    (Name of Issuer)


    Common Stock, $0.01 par value

    (Title of Class of Securities)


    36151G402

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    36151G402


    1Names of Reporting Persons

    BIGGER CAPITAL FUND L P
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    227,274.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    227,274.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    227,274.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.93 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    36151G402


    1Names of Reporting Persons

    Bigger Capital Fund GP, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    227,274.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    227,274.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    227,274.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.93 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    36151G402


    1Names of Reporting Persons

    District 2 Capital Fund LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    75,758.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    75,758.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    75,758.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.7 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    36151G402


    1Names of Reporting Persons

    District 2 Capital LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    75,758.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    75,758.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    75,758.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.7 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    36151G402


    1Names of Reporting Persons

    District 2 GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    75,758.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    75,758.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    75,758.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.7 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    36151G402


    1Names of Reporting Persons

    District 2 Holdings LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    75,758.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    75,758.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    75,758.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.7 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    36151G402


    1Names of Reporting Persons

    Bigger Michael
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    303,032.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    303,032.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    303,032.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.99 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    INTELLIGENT BIO SOLUTIONS INC.
    (b)Address of issuer's principal executive offices:

    135 West, 41st Street, 5th Floor, New York, NY 10036
    Item 2. 
    (a)Name of person filing:

    Bigger Capital Fund, LP ("Bigger Capital") Bigger Capital Fund GP, LLC ("Bigger GP") District 2 Capital Fund LP ("District 2 CF") District 2 Capital LP ("District 2") District 2 GP LLC ("District 2 GP") District 2 Holdings LLC ("District 2 Holdings") Michael Bigger Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."
    (b)Address or principal business office or, if none, residence:

    Bigger Capital Fund, LP 11700 West Charleston Blvd., #170-659 Las Vegas, NV, 89135 Bigger Capital Fund GP, LLC 11700 West Charleston Blvd., #170-659 Las Vegas, NV, 89135 District 2 Capital Fund LP 175 W. Carver Street Huntington, NY 11743 District 2 Capital LP 175 W. Carver Street Huntington, NY 11743 District 2 GP LLC 175 W. Carver Street Huntington, NY 11743 District 2 Holdings LLC 175 W. Carver Street Huntington, NY 11743 Michael Bigger 11700 West Charleston Blvd., #170-659 Las Vegas, NV, 89135
    (c)Citizenship:

    Bigger Capital Fund, LP Citizenship: Delaware Bigger Capital Fund GP, LLC Citizenship: Delaware District 2 Capital Fund LP Citizenship: Delaware District 2 Capital LP Citizenship: Delaware District 2 GP LLC Citizenship: Delaware District 2 Holdings LLC Citizenship: Delaware Michael Bigger Citizenship: USA
    (d)Title of class of securities:

    Common Stock, $0.01 par value
    (e)CUSIP No.:

    36151G402
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    As of January 31, 2025, Bigger Capital beneficially owned an aggregate of 227,274 shares of Common Stock, issuable upon the exercise of Warrants, which contain a 4.99% beneficial ownership limitation. Bigger GP, as the general partner of Bigger Capital, may be deemed to beneficially own an aggregate of 227,274 shares of Common Stock issuable upon the exercise of Warrants, which contain a 4.99% beneficial ownership limitation, beneficially owned by Bigger Capital. As of January 31, 2025, District 2 CF beneficially owned 75,758 shares of Common Stock issuable upon the exercise of Warrants, which contain a 4.99% beneficial ownership limitation. District 2, as the investment manager of District 2 CF, may be deemed to beneficially own the 75,758 shares of Common Stock issuable upon the exercise of Warrants, which contain a 4.99% beneficial ownership limitation, beneficially owned by District 2 CF. District 2 GP, as the general partner of District 2 CF, may be deemed to beneficially own the 75,758 shares of Common Stock issuable upon the exercise of Warrants, which contain a 4.99% beneficial ownership limitation, beneficially owned by District 2 CF. District 2 Holdings, as the managing member of District 2 GP, may be deemed to beneficially own the 75,758 shares of Common Stock issuable upon the exercise of Warrants, which contain a 4.99% beneficial ownership limitation, beneficially owned by District 2 CF. Mr. Bigger, as the managing member of Bigger GP and the managing member of District 2 Holdings, may be deemed to beneficially own the (i) aggregate of 227,274 shares of Common Stock, issuable upon the exercise of Warrants, beneficially owned by Bigger Capital, and (ii) 75,758 shares of Common Stock, issuable upon the exercise of Warrants, beneficially owned by District 2 CF. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any shares owned by another Reporting Person. Each of Bigger GP and Mr. Bigger disclaims beneficial ownership of shares beneficially owned by Bigger Capital. Each of District 2, District 2 GP, District 2 Holdings and Mr. Bigger disclaims beneficial ownership of the shares beneficially owned by District 2 CF. The filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.
    (b)Percent of class:

    The following percentages are based on 4,386,816 shares of Common Stock outstanding as of November 4, 2024, as reported in the Company's Form 10-Q for the six months ended September 30, 2024, and to reflect the addition of exercisable Warrants to the denominator and with respect to Mr. Bigger, the Blockers (as hereinafter defined). As of the close of business on January 31, 2025, (i) each of Bigger Capital and Bigger GP may be deemed to beneficially own approximately 4.93% of the outstanding shares, (ii) each of District 2 CF, District 2, District 2 GP and District 2 Holdings may be deemed to beneficially own 1.7% of the outstanding shares, and (iii) Mr. Bigger may be deemed to beneficially own approximately 4.99% of the outstanding shares. Pursuant to the terms of the Warrants, the Reporting Persons cannot exercise the Warrants to the extent the Reporting Persons or affiliates of the Reporting Persons would beneficially own, after any such exercise, more than 4.99% of the outstanding shares (the "Blockers"), and the percentage set forth in Row 11 of the cover page for Mr. Bigger as well the information in this Item 4(b) with respect to Mr. Bigger gives effect to the Blockers. Consequently, as of the date of the event which requires the filing of this statement, the Reporting Persons were not able to exercise all of the Warrants due to the Blockers.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     (ii) Shared power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     (iii) Sole power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

     (iv) Shared power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit 99.1. Previously Filed
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    BIGGER CAPITAL FUND L P
     
    Signature:/s/ Michael Bigger
    Name/Title:Michael Bigger, Managing Member of Bigger Capital Fund GP, LLC, its general partner
    Date:02/04/2025
     
    Bigger Capital Fund GP, LLC
     
    Signature:/s/ Michael Bigger
    Name/Title:Michael Bigger, Managing Member
    Date:02/04/2025
     
    District 2 Capital Fund LP
     
    Signature:/s/ Michael Bigger
    Name/Title:Michael Bigger, Managing Member of District 2 GP LLC, its general partner
    Date:02/04/2025
     
    District 2 Capital LP
     
    Signature:/s/ Michael Bigger
    Name/Title:Michael Bigger, Managing Member
    Date:02/04/2025
     
    District 2 GP LLC
     
    Signature:/s/ Michael Bigger
    Name/Title:Michael Bigger, Managing Member
    Date:02/04/2025
     
    District 2 Holdings LLC
     
    Signature:/s/ Michael Bigger
    Name/Title:Michael Bigger, Managing Member
    Date:02/04/2025
     
    Bigger Michael
     
    Signature:/s/ Michael Bigger
    Name/Title:Michael Bigger
    Date:02/04/2025
    Get the next $INBS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INBS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $INBS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Intelligent Bio Solutions Expects to Report Fiscal Second Quarter 2026 Revenue Growth of Approximately 48% Year-Over-Year, Surpassing $2 Million in Total Revenue for First Half of Fiscal Year

    Expected record fiscal second quarter revenue increase driven by expanding customer base and strong growth across all product categories Reader sales expected to post year-over-year growth of more than 100% in fiscal Q2, expanding installed base to drive sustained recurring cartridge revenue NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary, unaudited revenue results for the fiscal second quarter and first half 2026 ended December 31, 2025. The Company expects to report strong revenue growth across all pr

    2/5/26 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Initiates Additional Clinical Studies for FDA 510(k) Submission Supporting Planned Entry into Multi-Billion Dollar U.S. Market

    Clinical studies designed to support FDA clearance and planned commercial launch into the world's largest drug screening market  Company anticipates full data analysis by the end of March 2026; data to be incorporated into FDA 510(k) submission package NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the commencement of its clinical study program to support its new FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine. As part of

    1/28/26 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Announces Closing of $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

    NEW YORK, Jan. 02, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (NASDAQ:INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the closing of its previously announced private placement with two healthcare focused institutional investors priced at-the-market under Nasdaq rules of 2,298,850 shares of common stock (or pre-funded warrants in lieu thereof), Series K-1 warrants to purchase up to an aggregate of 2,298,850 shares of common stock and Series K-2 warrants to purchase up to an aggregate of 2,298,850 shares of common stock, at a combined purchase price of $4.35 per share of common stock (or

    1/2/26 5:00:00 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $INBS
    SEC Filings

    View All

    Intelligent Bio Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

    2/5/26 8:53:26 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

    1/28/26 5:15:25 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Intelligent Bio Solutions Inc.

    EFFECT - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

    1/22/26 12:15:16 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $INBS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Financial Officer Sakiris Spiro Kevin was granted 34,500 shares, increasing direct ownership by 10,952% to 34,815 units (SEC Form 4)

    4/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

    3/31/25 4:15:27 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Simeonidis Harry was granted 40,000 shares, increasing direct ownership by 9,804% to 40,408 units (SEC Form 4)

    4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

    9/27/24 5:00:16 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Sakiris Spiro Kevin was granted 34,500 shares, increasing direct ownership by 10,952% to 34,815 units (SEC Form 4)

    4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

    9/27/24 5:00:15 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $INBS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Intelligent Bio Solutions Inc.

    SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 7:16:17 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Intelligent Bio Solutions Inc.

    SC 13G - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 4:31:30 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $INBS
    Financials

    Live finance-specific insights

    View All

    Intelligent Bio Solutions Reports Fiscal 2026 First Quarter Financial Results and Operational Highlights, Delivering Record Revenue Growth

    Record quarterly revenue of $1.11 million, an increase of 32% sequentially and 28% year-over-year, driven by consumable cartridge sales and customer base expansion Gross profit margins increased 690 basis points year-over-year to 46.6%, reflecting improved operational efficiency and greater revenue percentage from higher margin cartridge sales NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal first quarter ended September 30, 2025. The fiscal 2026 first

    11/12/25 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Reports Fiscal 2025 Fourth Quarter and Full Year Results, Highlighting Progress on Planned U.S. Market Expansion, Revenue Growth and Increased Operational Efficiencies

    Company advanced efforts to secure U.S. FDA 510(k) clearance to advance on path towards planned U.S. market expansion beyond Forensic Use Only settings Fourth quarter sequential and year-on-year revenue growth of 16%, supported by increased demand for drug testing cartridges NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal fourth quarter and full-year ended June 30, 2025. Fiscal 2025 marked a year of growth for the Company, driven by higher-margin cart

    8/15/25 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results and Key Operational Achievements

    20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nine months ended March 31, 2025  35 new accounts and international growth during Q3 bring total active accounts to over 450 NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal third quarter and nine months ended March 31, 2025, and provided a business update.   The Company delivered a st

    5/13/25 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care